AZD2936 Clinical Trials
2 recruitingBiologic
Phase 22Phase 11
Showing 1–2 of 2 trials
Recruiting
Phase 2
Molecular Residual Disease Interception in Locoregionally-Advanced High Risk HPV+ and HPV- HNSCC
Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC)
University Health Network, Toronto102 enrolled1 locationNCT05414032
Recruiting
Phase 1Phase 2
A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC
Non-Small-Cell Lung Carcinoma
AstraZeneca210 enrolled48 locationsNCT04995523